AgelessRx, Inc. has been selected as one of 10 Milestone 2 awardees in the $101 million XPRIZE Healthspan competition, giving the longevity-focused telehealth company a $1 million award and a place among the teams moving into the competition’s clinical testing phase. AgelessRx plans to expand its multi-intervention healthy aging strategy into a randomized, controlled study lasting one year and involving approximately 186 adults aged 50 to 90.
The award is significant, but its meaning requires careful separation from the clinical claims surrounding the program. XPRIZE said its judges selected the Milestone 2 awardees based on factors including scientific rationale, scalability, accessibility and readiness to enter the clinical trial phase. That makes the selection an important external endorsement of the research program’s readiness and potential, but it is not evidence that AgelessRx has established that its combination slows aging, reverses biological aging or produces durable clinical benefit.
That distinction is particularly important because AgelessRx is attempting something more complicated than testing a single investigational medicine. Its pilot combined existing prescription therapies, supplements, exercise and meditation, creating a systems-based longevity intervention intended to influence muscle, cognitive and immune function simultaneously. The approach reflects a growing geroscience argument that age-related physiological decline involves multiple biological pathways, but it also creates a demanding clinical-trial problem: if several things are changed at once, determining which component caused an observed benefit becomes substantially harder.
What did AgelessRx actually show in its 90-day XPRIZE Healthspan pilot study?
AgelessRx’s semifinal-stage study was a randomized, placebo-controlled pilot involving adults aged 60 to 80 who showed indicators of age-related functional decline. The company reported that 26 participants were enrolled and 18 were included in the final analysis, with a mean age of 64.7 years and women accounting for 77.8% of the analyzed population. Participants were randomized among a control group and two increasingly intensive intervention groups.
The Multi-Therapy group received low-dose naltrexone, metformin, NAD+ nasal spray and vitamin B12, alongside structured exercise and guided meditation. The Comprehensive Therapy group added low-dose rapamycin, a glutathione patch and AgelessRx’s Infinite Longevity Support supplement. The control group received vitamin C and vitamin E, general exercise guidance and a neutral listening activity rather than the guided meditation program.
That design allowed AgelessRx to test whether a broad intervention package was feasible and produced signals worth investigating, but it was not structured to determine whether metformin, rapamycin, low-dose naltrexone, NAD+, exercise, meditation or another component was independently responsible for an outcome. Differences in the lifestyle programs between the active and control groups add another layer of interpretive difficulty because the active intervention was effectively a drug, supplement and behavioral package rather than an isolated pharmacological treatment.
AgelessRx reported several encouraging directional findings. PhenoAge declined in all three groups, with the Multi-Therapy group recording the largest average reduction at 1.84 years and five of six participants in the Comprehensive Therapy group showing improvement. Active groups also reported greater improvements in several sleep and quality-of-life measures, while both active groups largely preserved lean mass as the control group recorded an average 1.75-kilogram loss.
Yet some of the endpoints that matter most to XPRIZE were less convincing at this early stage. Cognitive testing produced small and inconsistent changes, while VO2 max results were mixed across all three groups. AgelessRx itself describes the 18-person analysis as a pilot that is too small to support definitive conclusions, which is the appropriate frame for the results.
Does a 1.84-year decline in PhenoAge mean participants actually reversed aging?
This may become the most important distinction as longevity companies increasingly use biological-age measurements in clinical studies. PhenoAge and related aging biomarkers are designed to capture biological patterns associated with aging, disease risk and mortality more effectively than chronological age alone, giving researchers potentially useful tools for studying interventions over periods far shorter than a human lifespan. PhenoAge-related methodologies have been associated with morbidity and mortality risk in population studies.
However, a lower biological-age score should not automatically be translated into a claim that a participant has literally become younger or gained a specific number of additional healthy years. Researchers working on biomarkers of aging have stressed that no aging biomarker has yet been formally validated as a surrogate endpoint that can substitute for a direct clinical measure of how people function, feel or survive. A biomarker can therefore provide evidence of biological response without proving that an intervention has reduced future disability, disease or mortality.
The AgelessRx pilot itself illustrates why that caution matters. PhenoAge declined even in the control group, although the company reported larger reductions in the active groups. Meanwhile, cognitive and aerobic-fitness measurements did not produce comparably clear differentiation. The next study will therefore need to show that changes in aging-related biomarkers are accompanied by reproducible improvements in the functional outcomes that XPRIZE is explicitly trying to measure.
What does the safety evidence from the AgelessRx longevity pilot actually tell us?
Safety interpretation is another area where the larger trial should materially improve the evidence base. AgelessRx monitored 39 blood biomarkers and reported no clinically concerning aggregate changes involving liver, kidney, immune or other organ-system markers in the active groups, although some lipid and red blood cell indices changed in the Comprehensive Therapy arm.
The company also reported that seven of the 26 enrolled participants, or 27%, experienced at least one adverse event and that three participants withdrew. One serious adverse event, a myocardial infarction in a participant assigned to the Multi-Therapy group, was reported and assessed as possibly associated with physical activity. The available disclosure does not establish that the pharmacological intervention caused that event, so it would be inappropriate to attribute it to the drug combination.
The broader lesson is that stable laboratory values in a small, short study cannot establish the longer-term safety of a multi-drug strategy. Larger enrollment and a full year of observation should provide substantially more exposure time for assessing tolerability, discontinuations, adverse events and whether combining several pharmacological and lifestyle interventions creates clinically relevant interactions that a 90-day feasibility study could not reliably detect.
How will the planned 186-person AgelessRx XPRIZE trial change the evidence?
AgelessRx says the finals program will expand the experiment to approximately 186 adults between 50 and 90 years of age and extend treatment and observation to one year. The company has also indicated that its proposed next-stage intervention would consolidate the active strategy and add low-dose tirzepatide, sermorelin, structured progressive resistance training and personalized health coaching.
That scale-up matters because the fundamental question now changes. The pilot asked whether AgelessRx could recruit participants, deliver a complicated decentralized intervention, monitor multiple functional and biological measures and generate a signal strong enough to justify more testing. The finals phase must move much closer to determining whether those signals survive a larger sample, longer follow-up and more rigorous comparison.
XPRIZE has created common research infrastructure intended to make that comparison more credible. Finalist studies are expected to run between 2026 and 2029, with the University of Utah Data Coordinating Center overseeing trial and data management and the University of California San Diego Stein Institute for Research on Aging coordinating shared laboratories, biomarkers and biological sample storage. XPRIZE says the competition will culminate in 2030 with a grand prize of up to $81 million.
There is nevertheless an interesting trade-off in AgelessRx’s approach. Adding more intervention components may increase the possibility of influencing several biological pathways simultaneously, which is central to the company’s hypothesis about aging. At the same time, a broader combination makes causal interpretation harder because a successful result may demonstrate that the entire package works better than control without establishing which individual elements are necessary, redundant or responsible for the effect.
Why does the $1 million award matter for the wider longevity medicine market?
The commercial significance extends beyond the prize money. AgelessRx operates a telehealth model through which several interventions included in its research program are already accessible to eligible patients after clinician evaluation. Its ability to integrate clinical research with a digital-care infrastructure gives the company a potential path for translating evidence into scalable service delivery more quickly than a conventional laboratory-focused research group.
That same integration makes evidence standards particularly important. An XPRIZE award is not a regulatory approval, and advancement in the competition does not establish an approved indication for slowing or reversing aging. The United States Food and Drug Administration evaluates drugs on the basis of safety and effectiveness for their intended uses, while dietary supplements are not subject to the same premarket approval process.
For AgelessRx, the value of the finals may therefore be less about generating a spectacular biological-age number and more about producing a sufficiently rigorous dataset connecting biomarker movements with objective muscle, cognitive and immune outcomes. If those functional effects can be reproduced across a much larger study population while maintaining an acceptable safety profile, the company would have considerably stronger evidence for its systems-based longevity model than it has today.
Can XPRIZE Healthspan push longevity research from biomarkers toward measurable function?
XPRIZE Healthspan is attempting to solve one of geroscience’s central development problems: human lifespan is too long for conventional longevity trials to wait decades for definitive outcomes. Instead, the competition is asking teams to demonstrate substantial restoration of muscle, cognitive and immune function in adults aged 50 to 90 within one year of treatment, using coordinated testing infrastructure and common scientific standards. XPRIZE selected 20 finalists for the next phase, with 10, including AgelessRx, receiving $1 million Milestone 2 awards.
For AgelessRx, winning the Milestone 2 award represents a meaningful transition from a small feasibility experiment to a substantially more consequential clinical test. The pilot produced enough evidence and operational readiness to persuade XPRIZE judges that the program deserved further testing, but its small analyzed population, multi-component design, inconsistent cognitive and aerobic-fitness findings and limited follow-up leave the central efficacy question unresolved.
The one-year trial will therefore carry far more weight than the award itself. If AgelessRx can demonstrate reproducible improvements in muscle, cognition and immune function alongside favorable biomarker changes, while also generating a clearer safety dataset, it could strengthen the case that combination gerotherapeutic strategies deserve a larger place in clinical longevity research. If the functional endpoints fail to separate convincingly from control, a falling biological-age score alone will be much harder to interpret as evidence that healthy human aging has materially changed.